Results 221 to 230 of about 810,018 (289)

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Predicting disease progression in multiple sclerosis with clinically accessible information and technology. [PDF]

open access: yesJ Neurol
Fuchs TAN   +74 more
europepmc   +1 more source

Developing medication independence: The experience of UK teenagers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims There is a progression through childhood from being provided medications by caregivers to having to take responsibility for medications yourself, but little is known about when the transition of adolescents managing medicines begins. The aim of this study was to obtain a cross‐sectional sample of UK adolescents and when they become independent ...
Holly Hutchins   +5 more
wiley   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

A Survey of Oncologists' Perceptions and Opinions Regarding Brain Imaging in Metastatic Renal Cell Carcinoma Within the UK. [PDF]

open access: yesCureus
Crosby BT   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy